Ponte Biosciences, Inc. is dedicated to addressing liver failure and advanced liver disease through innovative biotherapeutic solutions. The company has developed a Spheroid Reservoir Bioartificial Liver (SRBAL) System, which is designed to provide critical support for patients suffering from acute liver failure. This system leverages metabolically active primary hepatocytes, which are essential for performing liver functions, thereby offering a potential bridge for Intensive Care Unit (ICU) patients who require immediate intervention. The SRBAL System was developed in collaboration with the Mayo Clinic, highlighting its foundation in advanced scientific research and clinical application.

The company's focus on creating a cell-based bioartificial liver system underscores its commitment to addressing significant unmet medical needs in liver health. By utilizing a bioartificial approach, Ponte Biosciences aims to enhance patient outcomes and provide a viable alternative to traditional liver support methods. This innovative technology represents a promising advancement in the treatment of liver failure, positioning Ponte Biosciences at the forefront of biotherapeutic development in this critical area of healthcare.

United States

Ponte Biosciences, Inc. is a preclinical biotherapeutic company focused on developing a cell-based bioartificial liver system to treat acute forms of liver failure. The Company's Spheroid Reservoir Bioartificial Liver (SRBAL) system was developed at the Mayo Clinic and utilizes metabolically active primary hepatocytes (liver cells) to replace and/or supplement liver function for patients with liver failure being treated in the Intensive Care Unit (ICU).

Ponte Biosciences, Inc.

Company Details